c*e
2 楼
来了七年,只发了两篇七分一作。
回国有人要吗?
回国有人要吗?
f*u
3 楼
到居住地的政府(county)网页上该能查到你房产税的数额,很多地方这都是对公众公开的信
息
息
d*m
5 楼
关键取决于你是博士来的还是博后来的吧。前者你就比好多人强了,后者你基本就垫底
了。
了。
i*1
12 楼
工作量大吗?
M*n
14 楼
回国要抓紧阿.
过两年,国内的postdoc也发7分了,你就没有机会了。
在美国7年postdoc要拿faculty还是比较吃力的。
过两年,国内的postdoc也发7分了,你就没有机会了。
在美国7年postdoc要拿faculty还是比较吃力的。
b*M
24 楼
是不是 loser,在于自己的感受。从文章看,一般水平,还能混得下去。若干年后的问
题值得考虑。
题值得考虑。
k*o
26 楼
有CNS也算卢瑟了,呵呵,大家一起卢瑟
d*m
27 楼
这要不就是得瑟;要不就是发了CNS也不知道自己在干什么的那种。
l*1
29 楼
Please refer below company CEO his resume:
//www.epitomics.com/about/about_management/
Epitomics dot Com CEO Guoliang Yu, Ph.D.
Dr. Guo-Liang is currently the Chairman and President of Epitomics, Inc. an
emerging biotech company dedicated to the development of innovative next-
generation monoclonal antibodies. Before starting Epitomics, he was the
Senior Vice-President of Research and Development in Mendel Biotechnology
Inc. Dr. Yu has broad technological and scientific experiences in many
aspects of biotechnology. His interests cover genomics, molecular biology,
genetics, immunology, cancer biology, and plant physiology and drug
discovery. He is co-inventor and co-author of over 100 patents and
scientific articles. Dr. Yu received Ph.D. degree in Molecular Biology from
the University of California, Berkeley and B.S. degree in Biochemistry from
Fudan University, China. Guo-Liang conducted his Post-doctoral training in
Dr. Frederick Ausubel’s laboratory at the Harvard Medical School. Dr. Yu
founded Chinese Biopharmaceutical Association (CBA) headquartered in
Washington DC and is an Executive Member of several professional
organizations in U.S and China.
from
//tbiweb.org/tbi/editors.php
PhD studying
had
more papers from Molecular Biology from the University of California,
Berkeley
Cell (1991) 1st author:
//www.ncbi.nlm.nih.gov/pubmed/1934071
Cell (1990) 1st author
//www.ncbi.nlm.nih.gov/pubmed/1689810
-------
PD training only two papers from Harvard Medical School
unknown one journal 1st author
//www.ncbi.nlm.nih.gov/pubmed/8400373
Cell (1994) 3rd author
//www.ncbi.nlm.nih.gov/pubmed/7923358
citation:
//www.ncbi.nlm.nih.gov/pmc/articles/PMC144313/
-----
this kind of performance never can become tenure tracking faculty PI/AP in
US,
so DIHimself VB business in US and China from then...
plus
临床诊断试剂开发研究员(2名)
生物学,医学专业博士学历 xxx 从事临床诊断试剂
开发工作,领导并参与靶标设定,抗体开发、和产品质量评估相关的研发工作,具有扎
实的免疫学,生物化学,蛋白质操作知识及临床诊断试剂开发领域的知识及相关经验;
具有相关项目管理经验者优先;善于沟通,具有优秀的协作及协调能力;具有严谨的科
学训练及独立开展工作的能力,有成功开发项目经验者优先 YYY
//job.zjtcm.net/news/48201227153030.html
【在 c******e 的大作中提到】![](/moin_static193/solenoid/img/up.png)
: 来了七年,只发了两篇七分一作。
: 回国有人要吗?
//www.epitomics.com/about/about_management/
Epitomics dot Com CEO Guoliang Yu, Ph.D.
Dr. Guo-Liang is currently the Chairman and President of Epitomics, Inc. an
emerging biotech company dedicated to the development of innovative next-
generation monoclonal antibodies. Before starting Epitomics, he was the
Senior Vice-President of Research and Development in Mendel Biotechnology
Inc. Dr. Yu has broad technological and scientific experiences in many
aspects of biotechnology. His interests cover genomics, molecular biology,
genetics, immunology, cancer biology, and plant physiology and drug
discovery. He is co-inventor and co-author of over 100 patents and
scientific articles. Dr. Yu received Ph.D. degree in Molecular Biology from
the University of California, Berkeley and B.S. degree in Biochemistry from
Fudan University, China. Guo-Liang conducted his Post-doctoral training in
Dr. Frederick Ausubel’s laboratory at the Harvard Medical School. Dr. Yu
founded Chinese Biopharmaceutical Association (CBA) headquartered in
Washington DC and is an Executive Member of several professional
organizations in U.S and China.
from
//tbiweb.org/tbi/editors.php
PhD studying
had
more papers from Molecular Biology from the University of California,
Berkeley
Cell (1991) 1st author:
//www.ncbi.nlm.nih.gov/pubmed/1934071
Cell (1990) 1st author
//www.ncbi.nlm.nih.gov/pubmed/1689810
-------
PD training only two papers from Harvard Medical School
unknown one journal 1st author
//www.ncbi.nlm.nih.gov/pubmed/8400373
Cell (1994) 3rd author
//www.ncbi.nlm.nih.gov/pubmed/7923358
citation:
//www.ncbi.nlm.nih.gov/pmc/articles/PMC144313/
-----
this kind of performance never can become tenure tracking faculty PI/AP in
US,
so DIHimself VB business in US and China from then...
plus
临床诊断试剂开发研究员(2名)
生物学,医学专业博士学历 xxx 从事临床诊断试剂
开发工作,领导并参与靶标设定,抗体开发、和产品质量评估相关的研发工作,具有扎
实的免疫学,生物化学,蛋白质操作知识及临床诊断试剂开发领域的知识及相关经验;
具有相关项目管理经验者优先;善于沟通,具有优秀的协作及协调能力;具有严谨的科
学训练及独立开展工作的能力,有成功开发项目经验者优先 YYY
//job.zjtcm.net/news/48201227153030.html
【在 c******e 的大作中提到】
![](/moin_static193/solenoid/img/up.png)
: 来了七年,只发了两篇七分一作。
: 回国有人要吗?
b*y
33 楼
如果过来读书,很厉害
如果过来直接薄厚,中等吧,也没多卢瑟
大家都差不多
如果过来直接薄厚,中等吧,也没多卢瑟
大家都差不多
相关阅读
【打人,还是找抽?】:孟山都 vs. 张辰宇(ZZ)这种没有ASCP认证的证书班发的所谓证书有效吗?UCSD researcher shot by cofounderRe: 不是才冬奥吗,刘翔这翔怎么又出来恶心人了 (转载)求推荐好的V5 tag antibody 用于FACS and WB黑人的基因怎么那么强?求转基因的astrocyte和microglial cells11g这次当选中科院院士了一个朋友热衷写review借人气问priceline上bid成功之后还能取消么?有人能看到pubmed commons的评论吗?美国宿命---终结篇Vacuum manifold for 96-well plasmid prepRetraction: Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPKDC附近哪个学校有药剂师的program?求篇全文 - got!米饭miRNA进体内的文章被指名打脸了这回知道以后要买谁的试剂了!--NeoBiolab on Jimmy Kimmel (转 (转载)[分享] Research Commercialization Introductory Course (Free, 11/14/13-12/12/13)请教个endnote的问题, 怎么在reference list加描述